Cortexyme, Inc., a South San Francisco, California-based developer of therapeutics to alter the course of Alzheimer’s and other degenerative disorders, raised $15m in Series A financing.
The round was led by Pfizer Inc. new participation from Takeda Pharmaceutical Company Ltd., through its venture arm, existing investors Dolby Family Ventures and others. In conjunction with the funding, Margi McLoughlin, Executive Director, Worldwide Business Development for Pfizer, Ilan Zipkin, Senior Investment Director at Takeda, and David Lamond, President of Lamond Capital will join Cortexyme’s Board of Directors.
The company intends to use the funds for ongoing development of novel therapeutics and diagnostics for Alzheimer’s disease and other degenerative disorders.
Led by Casey Lynch, CEO, Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration currently testing several patent-pending lead therapeutics in preclinical studies.
The company had previously raised $1.025m including an investment award from Breakout Labs.